Whole cell inactivated poly-bacterial preparation MV130 effect on nasal mucosal immunity and experimental human pneumococcal carriage: double-blind randomised controlled trial with controlled human infection model.

Ndaferankhande J, Jambo KC, Chikaonda T, Tembo G, Conejero L, Henrion MYR, Kudowa E, Lipunga G, Chirwa AE, Nsomba E, Mayuni MC, Mailboy M, Sigoloti A, Dzonzi B, Mangani E, Nkhoma V, Songolo S, Toto N, Thole F, Banda NPK, Galafa B, Kadzanja G, Kamanga MP, Chimgoneko L, Nthandira T, Tembo BM, Muyaya A, Makhaza L, Lipenga B, Katangwe V, Chiwala G, Grigg J, Gordon SB, MARVELS consortium

Open source

DOI
10.1016/j.ebiom.2026.106443
Published
2026 Sep
Container
EBioMedicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ebiom.2026.106443,
  title = {Whole cell inactivated poly-bacterial preparation MV130 effect on nasal mucosal immunity and experimental human pneumococcal carriage: double-blind randomised controlled trial with controlled human infection model.},
  author = {Ndaferankhande J and Jambo KC and Chikaonda T and Tembo G and Conejero L and Henrion MYR and Kudowa E and Lipunga G and Chirwa AE and Nsomba E and Mayuni MC and Mailboy M and Sigoloti A and Dzonzi B and Mangani E and Nkhoma V and Songolo S and Toto N and Thole F and Banda NPK and Galafa B and Kadzanja G and Kamanga MP and Chimgoneko L and Nthandira T and Tembo BM and Muyaya A and Makhaza L and Lipenga B and Katangwe V and Chiwala G and Grigg J and Gordon SB and MARVELS consortium},
  year = {2026},
  journal = {EBioMedicine},
  doi = {10.1016/j.ebiom.2026.106443},
  url = {https://doi.org/10.1016/j.ebiom.2026.106443}
}

RIS

TY  - JOUR
TI  - Whole cell inactivated poly-bacterial preparation MV130 effect on nasal mucosal immunity and experimental human pneumococcal carriage: double-blind randomised controlled trial with controlled human infection model.
AU  - Ndaferankhande J
AU  - Jambo KC
AU  - Chikaonda T
AU  - Tembo G
AU  - Conejero L
AU  - Henrion MYR
AU  - Kudowa E
AU  - Lipunga G
AU  - Chirwa AE
AU  - Nsomba E
AU  - Mayuni MC
AU  - Mailboy M
AU  - Sigoloti A
AU  - Dzonzi B
AU  - Mangani E
AU  - Nkhoma V
AU  - Songolo S
AU  - Toto N
AU  - Thole F
AU  - Banda NPK
AU  - Galafa B
AU  - Kadzanja G
AU  - Kamanga MP
AU  - Chimgoneko L
AU  - Nthandira T
AU  - Tembo BM
AU  - Muyaya A
AU  - Makhaza L
AU  - Lipenga B
AU  - Katangwe V
AU  - Chiwala G
AU  - Grigg J
AU  - Gordon SB
AU  - MARVELS consortium
PY  - 2026
JO  - EBioMedicine
DO  - 10.1016/j.ebiom.2026.106443
UR  - https://doi.org/10.1016/j.ebiom.2026.106443
ER  - 

APA

J, N., KC, J., T, C., G, T., L, C., MYR, H., E, K., G, L., AE, C., E, N., MC, M., M, M., A, S., B, D., E, M., V, N., S, S., N, T., F, T., NPK, B., B, G., G, K., MP, K., L, C., T, N., BM, T., A, M., L, M., B, L., V, K., G, C., J, G., SB, G., & consortium, M. (2026). Whole cell inactivated poly-bacterial preparation MV130 effect on nasal mucosal immunity and experimental human pneumococcal carriage: double-blind randomised controlled trial with controlled human infection model.. EBioMedicine. https://doi.org/10.1016/j.ebiom.2026.106443

Source records